Synopsis
Synopsis
0
EU WC
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Compound 545
2. Exypaque
3. Iohexol 350
4. Nycodenz
5. Omnipaque
1. 66108-95-0
2. Omnipaque
3. Nycodenz
4. Exypaque
5. Iohexolum
6. Omnipaque 240
7. Omnipaque 70
8. Omnipaque 140
9. Omnipaque 180
10. Omnipaque 210
11. Omnipaque 300
12. Omnipaque 350
13. Win 39424
14. Oraltag
15. Win-39424
16. Chebi:31709
17. N,n'-bis(2,3-dihydroxypropyl)-5-(n-(2,3-dihydroxypropyl)acetamido)-2,4,6-triiodoisophthalamide
18. 5-[acetyl(2,3-dihydroxypropyl)amino]-1-n,3-n-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
19. 5-[acetyl(2,3-dihydroxypropyl)amino]-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide
20. N1,n3-bis(2,3-dihydroxypropyl)-5-(n-(2,3-dihydroxypropyl)acetamido)-2,4,6-triiodoisophthalamide
21. 4419t9mx03
22. Nsc-759636
23. Ncgc00166000-01
24. Dsstox_cid_3157
25. 5-(n-2,3-dihydroxypropylacetamido)-2,4,6-triiodo-n,n'-bis(2,3-dihydroxypropyl)isophthalamide
26. Dsstox_rid_76895
27. Dsstox_gsid_23157
28. 1,3-benzenedicarboxamide, 5-(acetyl(2,3-dihydroxypropyl)amino)-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-
29. Histodenz
30. Iohexolum [inn-latin]
31. 1,3-benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-n1,n3-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-
32. 5-[acetyl(2,3-dihydroxypropyl)amino]-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
33. 5-[n-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodo-n,n'-bis(2,3-dihydroxypropyl)isophthalamide
34. Smr000857075
35. Einecs 266-164-2
36. Brn 2406632
37. Unii-4419t9mx03
38. Omnipaque (tn)
39. 1,3-benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-
40. N,n'-bis(2,3-dihydroxypropyl)-5-[n-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodoisophthalamide
41. Prestwick_802
42. Cas-66108-95-0
43. Iohexol [usan:usp:inn:ban:jan]
44. Iohexol [vandf]
45. Iohexol [usan]
46. Iohexol [inn]
47. Iohexol [jan]
48. Iohexol [mi]
49. Iohexol [mart.]
50. Prestwick0_000512
51. Prestwick1_000512
52. Prestwick2_000512
53. Prestwick3_000512
54. Iohexol [usp-rs]
55. Iohexol [who-dd]
56. Iohexol [who-ip]
57. Nycodenz;omnipaque;exypaque
58. Ec 266-164-2
59. Iohexol, Analytical Standard
60. Schembl26501
61. Bspbio_000463
62. Mls001332585
63. Mls001332586
64. Mls002153854
65. Iohexol (jp17/usp/inn)
66. Iohexol [ep Impurity]
67. Iohexol [orange Book]
68. Spbio_002384
69. Iohexol [ep Monograph]
70. Bpbio1_000511
71. Iohexol [usp Monograph]
72. Chembl1200455
73. Dtxsid6023157
74. Bcbcmap01_000051
75. Iohexolum [who-ip Latin]
76. Hms1569h05
77. Hms2096h05
78. Hms2235d07
79. Hms3369o04
80. Hms3713h05
81. Albb-028959
82. Amy21804
83. Bcp31800
84. Hy-b0594
85. Tox21_112286
86. Bdbm50247977
87. Iohexol (mixture Of Isomers)
88. Mfcd00077732
89. S4531
90. Akos015895399
91. Tox21_112286_1
92. Ac-1934
93. Ccg-220512
94. Db01362
95. Nsc 759636
96. Smp1_000152
97. Ncgc00166000-02
98. Ncgc00166000-04
99. As-12699
100. Ft-0627276
101. I0903
102. D01817
103. D91214
104. Histodenz(tm), Nonionic Density Gradient Medium
105. 108i950
106. A835339
107. Q410683
108. Sr-01000838892
109. Sr-01000838892-2
110. Iohexol, European Pharmacopoeia (ep) Reference Standard
111. Iohexol, United States Pharmacopeia (usp) Reference Standard
112. 5-(n-dhp-acetamido)-2,4,6-triiodo-n,n'-b Is-dhp-isophthalami
113. Iohexol, Pharmaceutical Secondary Standard; Certified Reference Material
114. Iohexol For Peak Identification, European Pharmacopoeia (ep) Reference Standard
115. 1,3-benzenedicarboxamide, 5-(acetyl(2,3-dihydroxypropyl)amino)-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo
116. 1-n,3-n-bis(2,3-dihydroxypropyl)-5-[n-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide
117. 5-[acetyl(2,3-dihydroxypropyl)amino]-n1,n3-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
118. N1,n3-bis(2,3-dihydroxypropyl)-5-[n-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide
119. N1,n3-bis[2,3-bis(oxidanyl)propyl]-5-[2,3-bis(oxidanyl)propyl-ethanoyl-amino]-2,4,6-tris(iodanyl)benzene-1,3-dicarboxamide
| Molecular Weight | 821.1 g/mol |
|---|---|
| Molecular Formula | C19H26I3N3O9 |
| XLogP3 | -3 |
| Hydrogen Bond Donor Count | 8 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 12 |
| Exact Mass | 820.8803 g/mol |
| Monoisotopic Mass | 820.8803 g/mol |
| Topological Polar Surface Area | 200 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 653 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 3 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Omnipaque 180 |
| PubMed Health | Iohexol (Injection) |
| Drug Classes | Radiological Non-Ionic Contrast Media |
| Active Ingredient | Iohexol |
| Dosage Form | Solution |
| Route | Injection, oral, rectal |
| Strength | 38.8% |
| Market Status | Prescription |
| Company | Ge Healthcare |
| 2 of 4 | |
|---|---|
| Drug Name | Omnipaque 240 |
| Active Ingredient | Iohexol |
| Dosage Form | Solution |
| Route | Injection, oral, rectal |
| Strength | 51.8% |
| Market Status | Prescription |
| Company | Ge Healthcare |
| 3 of 4 | |
|---|---|
| Drug Name | Omnipaque 180 |
| PubMed Health | Iohexol (Injection) |
| Drug Classes | Radiological Non-Ionic Contrast Media |
| Active Ingredient | Iohexol |
| Dosage Form | Solution |
| Route | Injection, oral, rectal |
| Strength | 38.8% |
| Market Status | Prescription |
| Company | Ge Healthcare |
| 4 of 4 | |
|---|---|
| Drug Name | Omnipaque 240 |
| Active Ingredient | Iohexol |
| Dosage Form | Solution |
| Route | Injection, oral, rectal |
| Strength | 51.8% |
| Market Status | Prescription |
| Company | Ge Healthcare |
Iohexol ia used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.
Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
Contrast Media
Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)
V08AB02
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
V - Various
V08 - Contrast media
V08A - X-ray contrast media, iodinated
V08AB - Watersoluble, nephrotropic, low osmolar x-ray contrast media
V08AB02 - Iohexol
Absorption
Small amounts are absorbed through the bladder via intravesical instillation. Following intrauterine instillation, the majority of the medium within the uterine cavity is discharged into the vagina immediately upon termination of procedure. However, any medium retained in the uterine or peritoneal cavity is absorbed systemically within 60 minutes. May not be absorbed for up to 24 hours if tubes are obstructed and dilated.
Route of Elimination
Iohexol is absorbed from cerebrospinal fluid (CSF) into the bloodstream and is eliminated by renal excretion. No significant metabolism, deiodination, or biotransformation occurs.
Volume of Distribution
350-849 mL/kg
Clearance
109 mL/min [Adult patients receiving 16-18 ml of iohexol (180 mgI/mL) by lumbar intrathecal injection]
Intrathecal half-life is 3.4 hours (mean). Intravascular is approximately 2 hours (with normal renal function).
Organic iodine compounds block x-rays as they pass through the body, thereby allowing body structures containing iodine to be delineated in contrast to those structures that do not contain iodine. The degree of opacity produced by these compounds is directly proportional to the total amount (concentration and volume) of the iodinated contrast agent in the path of the x-rays. After intrathecal administration into the subarachnoid space, diffusion of iohexol in the CSF allows the visualization of the subarachnoid spaces of the head and spinal canal. After intravascular administration, iohexol makes opaque those vessels in its path of flow, allowing visualization of the internal structures until significant hemodilution occurs.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Parenteral
Topical
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
